A common blood test for ovarian cancer is more likely to fall short for Black and Native American women, according to a new ...

A common blood test may miss ovarian cancer in some Black and Native American patients, delaying their treatment, a new study ...

A comparison of patients with and without BRCA gene mutations receiving prophylactic risk-reduction surgery suggest ...

A new study finds that a common blood test for ovarian cancer may miss some Black and Native American patients, delaying ...

Nemvaleukin alfa with pembrolizumab missed the overall survival primary end point in ARTISTRY-7 for platinum-resistant ...

The first patient was dosed in a phase 3 trial of IBI354 for platinum-resistant ovarian cancer with HER2 expression.

It is imperative to align strategies that can prevent ovarian cancer while also strengthening support for patients, caregivers, and health systems that are confronted by it,” the researchers wrote.

Nemvaleukin alfa is an investigational engineered fusion protein composed of modified interleukin-2 (IL-2) and the high-affinity IL-2 alpha receptor chain.

The phase 3 trial design evaluating IMNN-001 in newly diagnosed advanced ovarian cancer has been finalized among regulatory ...

In just a few weeks, you will have a special opportunity to rediscover downtown La Grange and support a good cause.

Black and American Indian patients are less likely to have elevated cancer antigen-125 levels at ovarian cancer diagnosis.